AxoGen (AXGN)
(Delayed Data from NSDQ)
$5.75 USD
-0.23 (-3.85%)
Updated May 10, 2024 04:00 PM ET
After-Market: $5.76 +0.01 (0.17%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.75 USD
-0.23 (-3.85%)
Updated May 10, 2024 04:00 PM ET
After-Market: $5.76 +0.01 (0.17%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Zacks News
Here's Why "Trend" Investors Would Love Betting on AxoGen (AXGN)
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 93.33% and 2.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Si-Bone (SIBN) delivered earnings and revenue surprises of 8.89% and 0.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Orthofix (OFIX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Orthofix (OFIX) delivered earnings and revenue surprises of 550% and 2.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
AxoGen (AXGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?
by Zacks Equity Research
Here is how Catalyst Pharmaceutical (CPRX) and AxoGen (AXGN) have performed compared to their sector so far this year.
AxoGen (AXGN) Soars 8.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Wall Street Analysts Think AxoGen (AXGN) Could Surge 89%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at an 89.4% upside potential for AxoGen (AXGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Are Medical Stocks Lagging Acadia Healthcare (ACHC) This Year?
by Zacks Equity Research
Here is how Acadia Healthcare (ACHC) and AxoGen (AXGN) have performed compared to their sector so far this year.
AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 60% and 5.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of -17.65% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 38.46% and 0.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AxoGen (AXGN) Q4 Earnings Expected to Decline
by Zacks Equity Research
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 25.00% and -9.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cousins Properties' (CUZ) Heights Union Buyout Fails to Drive Stock
by Zacks Equity Research
The acquisition of Heights Union is in line with Cousins Properties' (CUZ) efforts to enhance its portfolio quality with trophy assets.
AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 25.00% and 3.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) Stock Jumps 12.5%: Will It Continue to Soar?
by Zacks Equity Research
AxoGen (AXGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 52.94% and 8.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 130.77% and 11.06%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 40.00% and 5.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AxoGen (AXGN) Q2 Earnings Expected to Decline
by Zacks Equity Research
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: AxoGen (AXGN) Q1 Earnings Expected to Decline
by Zacks Equity Research
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.